{"filings":[{"id":1325876,"accession_number":"0001437749-26-021938","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-06-29T17:04:56+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"NRC Health shareholders approve charter amendments removing supermajority voting, director removal restrictions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved removing supermajority voting requirements (19.0M for, 0.97M against).","Restrictions on removal of directors without cause eliminated (19.9M for, 16.6k against).","Voting requirement for written consent changed from unanimous to majority of voting power (18.9M for, 1.0M against).","Seven directors elected; say-on-pay approved with 17.1M for, 2.9M against; KPMG ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98384,"accession_number":"0001437749-26-013646","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.","Cash bonuses approved: ~$1.9M for Green, ~$0.5M each for Hrdy and Monich to cover estimated taxes from award changes.","Expected Q2 2026 expense of $9.4M: ~$6.5M non-cash accelerated equity comp and ~$2.9M cash bonus expense.","Effective tax rate impacted by non-deductibility of amounts; future period charges eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98383,"accession_number":"0001437749-26-013641","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q1 revenue up 4% to $34.8M; TRCV record $152.1M (+13% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.2M ($0.14 diluted EPS); adjusted net income $4.6M ($0.21 adjusted diluted EPS).","Adjusted EBITDA $9.4M (27% of revenue); cash flow from operations $7.2M up 8% YoY.","Total Recurring Contract Value (TRCV) $152.1M, up 13% YoY, sixth consecutive quarterly increase.","Company signed the largest deal in its 45-year history; new sales and retention reached multi-year highs.","Free cash flow $5.4M (15% of revenue); revenue $34.8M, first YoY growth since 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":34803000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98382,"accession_number":"0001437749-26-012850","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"NRC Health declassifies board, formalizes name change; CFO restricted stock amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to NRC Health from National Research Corp; 'NRC' ticker unchanged; no shareholder vote required.","Board declassified: all directors will face annual elections; five directors resigned residual terms effective before June 23, 2026 meeting.","Resigning directors: Berwick, Green, Hays, Lockhart, Nunnelly; all seven incumbents nominated for reelection at 2026 annual meeting.","CFO Shane Harrison's restricted stock award (172,000 shares, Sept 2025) amended to permit voting and dividends on unvested shares.","Amended Bylaws set max board size at 12, update meeting/notice deadlines, and formalize Chair position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113805,"accession_number":"0001437749-26-006945","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NRC Health TRCV reaches all-time high of $152M, up 13% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TRCV surpassed $152 million as of March 4, 2026, a new all-time high for NRC Health.","TRCV increased approximately 6% from Q4 2025 and 13% year-over-year.","CEO Trent Green attributed the milestone to customer confidence and platform value.","The update does not reflect complete financial results for Q1 ending March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113804,"accession_number":"0001437749-26-002726","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q4 2025 revenue $35.2M; TRCV up 8% YoY to $144.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net income $1.8M ($0.08 diluted EPS); adjusted net income $3.4M ($0.16 diluted EPS).","Adjusted EBITDA $8.7M (25% of revenue); operating cash flow $7.2M, up 13% YoY.","Full-year 2025 revenue $137.4M; GAAP net income $11.6M ($0.50 EPS); adjusted net income $20.7M ($0.93 EPS).","TRCV of $144.1M grew 8% YoY and sequentially for the fifth consecutive quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":50.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":137390000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130215,"accession_number":"0001437749-25-031819","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q3 2025: TRCV up 8% to $141.7M; Adj EBITDA +11% YoY to $10.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.6M (+2% QoQ); GAAP net income $4.1M (12% of revenue); Adj net income $5.0M (14% of revenue).","GAAP EPS $0.18; adjusted EPS $0.23 on 22.1M diluted shares.","Cash from operations $13.8M (+46% YoY), representing 40% of total revenue.","Total Recurring Contract Value (TRCV) $141.7M, up 8% YoY; fourth consecutive quarterly growth.","CEO Trent Green cited strong sales and improved customer retention as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":102196000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146773,"accession_number":"0001437749-25-027942","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NRC Health names Shane Harrison CFO effective Sept 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shane Harrison appointed Executive VP and CFO, succeeding Michael D. Hays as principal financial officer.","Annual base salary of $400,000; $100,000 signing bonus subject to pro-rated repayment if terminated within one year.","Grant of 172,000 restricted shares vesting over three years; accelerated vesting on double-trigger change in control.","Harrison most recently SVP Finance and IR at PowerSchool; prior roles at NAVEX Global and FLIR Systems."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146772,"accession_number":"0001437749-25-023676","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q2 2025: TRCV grows 2% sequentially; net margin 0% on exec comp; adj EBITDA margin 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TRCV grew 2% sequentially, third consecutive quarter of growth and highest since Q1 2021.","Net margin 0% due to non-recurring executive compensation; adjusted EBITDA margin 30%.","Declared $0.12 quarterly dividend; payable Oct 10, 2025 to holders of record Sept 26, 2025.","Repurchased 381,736 shares at $14.96 avg in Q2; $16.1M returned to shareholders YTD.","New CEO Trent Green reinstated quarterly earnings call; cites strong customer feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":67588000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165208,"accession_number":"0001437749-25-015965","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"National Research shareholders approve 2025 Omnibus Incentive Plan, elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Donald M. Berwick and Stephen H. Lockhart elected as directors for three-year terms.","KPMG LLP ratified as independent auditor for 2025 with 21,710,551 votes for.","Say-on-pay advisory vote passed with 20,655,974 for, 217,494 against.","2025 Omnibus Incentive Plan approved with 16,852,672 for, 4,017,318 against, replacing prior plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165207,"accession_number":"0001437749-25-013363","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"National Research Corporation Reports Q1 2025 Results and Announces Share Repurchase Program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total recurring value contract value increased sequentially for second consecutive quarter.","Board approved repurchase of up to one million additional shares of common stock.","Declared quarterly cash dividend of $0.12 per share payable July 11, 2025.","Operating expenses declined in the first quarter of 2025.","Trent Green to join as CEO in June 2025; introductory calls available June 9-10."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":33551000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165206,"accession_number":"0001437749-25-012697","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research designates CEO Hays as interim PFO, appoints Freeman as CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Michael D. Hays designated principal financial officer; will serve as PEO and PFO until Trent Green becomes CEO on June 1, 2025.","Jordan N. Freeman appointed Chief Accounting Officer and principal accounting officer, effective April 18, 2025.","No compensation changes were made in connection with either appointment.","Freeman previously served in accounting leadership roles at Nelnet and as a senior audit associate at Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165205,"accession_number":"0001437749-25-011529","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NRC adjusts exec compensation ahead of CEO transition; COO gets 100k share grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trent Green to become CEO and director effective June 1, 2025, as previously announced.","COO Helen Hrdy received 100,000 restricted shares; cash bonus of 66 2/3% of share value; base salary stays $400k.","Hrdy forfeited unvested performance option for 100k shares; prior severance and 2024 LTIP terminated.","Same compensation changes apply to Chief Corporate Development Officer Andrew Monnich.","CEO Michael Hays' compensation unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182886,"accession_number":"0001008886-25-000033","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NRC appoints Trent Green as CEO effective June 1, 2025; Hays becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trent Green named CEO effective June 1, 2025; current CEO Mike Hays transitions to Chairman.","Green's compensation: $1.25M base salary, 500,000 restricted shares, cash signing bonus equal to 66.67% of share value.","Linda Stacy appointed Interim Principal Financial Officer through March 31, 2025 at $150/hour.","Green most recently CEO of Amazon One Medical; previously COO at Legacy Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182885,"accession_number":"0001437749-25-003231","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"National Research enters $140M credit facility ($30M revolver + $110M term loan); $62.4M drawn at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit agreement dated Feb 6, 2025 amends and restates 2020 facility with First National Bank of Omaha.","Revolving credit facility of $30M; $3.5M outstanding at close; matures in 3 years.","Delayed draw term loan of $110M with accordion up to $25M; $62.4M drawn; matures in 5 years.","Interest at Term SOFR + 2.25% to 2.75% based on leverage; covenants: fixed charge coverage ≥1.10x, leverage ≤3.50x.","Facility secured by substantially all assets; restricts stock repurchases and acquisitions subject to exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182884,"accession_number":"0001437749-25-001928","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.","Net indebtedness $58.5M; total recurring contract value $133.2M at Dec 31, 2024.","Returned $10.1M to shareholders: $7.3M in stock repurchases (393k shares) plus $0.12/share dividend.","Chief Product Technology Officer Chrisophe Louvion resigned effective Jan 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":143060000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199471,"accession_number":"0001437749-24-035132","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research CFO/PAO Linda Stacy to retire effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Linda Stacy notified company of retirement as Secretary, Principal Financial Officer, and Principal Accounting Officer.","Retirement effective December 31, 2024; no successor named yet.","Stacy served over 18 years; Board expressed gratitude for her service.","Departure creates a vacancy in key financial and accounting leadership roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199470,"accession_number":"0001437749-24-032151","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q3 revenue falls 5.5% to $35.8M; EPS drops to $0.24 from $0.32","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.8M vs $37.9M a year ago; diluted EPS $0.24 vs $0.32.","Net indebtedness $50.2M at Sept 30, 2024; Total Recurring Contract Value $131.6M.","Returned $11.5M to stockholders: $8.6M share repurchases (395k shares) and $2.9M dividends.","Board declared $0.12 quarterly dividend payable Jan 10, 2025 to holders of record Dec 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":106154000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199469,"accession_number":"0001437749-24-031195","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"National Research appoints Helen L. Hrdy as COO effective Oct 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Helen L. Hrdy, 60, appointed Chief Operating Officer on October 14, 2024.","Previously served as Chief Customer Officer since January 2024 and Chief Growth Officer from Jan 2020 to Jan 2024.","Hrdy has held various roles with the company since 2000, including Senior Vice President, Customer Success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215505,"accession_number":"0001437749-24-024947","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"NRC Health Q2 revenue $35M, EPS $0.26; amends credit; acquires NOBL Health","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue ~$35M vs ~$36M YoY; diluted EPS $0.26 vs $0.29 YoY; TRCV $138M at June 30.","Credit agreement amended: maturity extended to May 2027; term loans bear SOFR+2.35% with 10-year amort.","Acquired NOBL Health on July 15 for ~$6M cash + up to $1M earnout; NOBL had ~$2M TRCV.","Board declared $0.12/share quarterly dividend, payable Oct 11, record Sep 27.","~1.1M shares remain under repurchase plan; no buybacks in Q2 pending amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":70334000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234841,"accession_number":"0001437749-24-016208","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NRC shareholders elect directors, ratify KPMG, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael D. Hays re-elected with 97.1% of votes cast; John N. Nunnelly with 91.2%.","KPMG ratified as independent auditor for 2024 with 99.2% approval.","Non-binding advisory vote on executive compensation approved with 98.9% support.","Approximately 96% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234840,"accession_number":"0001437749-24-015131","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NRC Health appoints Linda Stacy as PFO; Q1 dividend $0.12; $40M net debt; no GAAP results disclosed","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Linda Stacy appointed Principal Financial Officer effective May 7, 2024; retains roles as PAAO and Secretary.","Quarterly cash dividend of $0.12/share declared, payable July 15, 2024 to holders of record June 28, 2024.","Q1 2024 returned $18M to stockholders via dividends and share repurchases; $4M invested in innovation.","Net debt ~$40M; available liquidity includes $23M line of credit and $56M delayed draw term facility.","Press release provides no GAAP revenue or EPS figures; CEO cites upcoming AI features and expanded product suite."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":35313000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252696,"accession_number":"0001437749-24-003940","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NRC Q4 2023 EPS $0.36; CFO Karas to retire March 31, dividend $0.12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 diluted EPS $0.36 vs $0.27; prior year included $0.10 Canadian exit charge.","Revenue flat at $38M as new core sales offset non-core revenue declines.","CFO Kevin Karas to retire effective March 31, 2024; one-year base salary continuation.","Linda Stacy promoted to Principal Accounting Officer, effective March 31, 2024.","Quarterly dividend $0.12 per share, payable April 15, 2024, record March 29."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":148580000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252695,"accession_number":"0001437749-24-001540","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NRC Health promotes Hrdy to Chief Customer Officer, adds three execs, ties compensation to $170M TRCV target","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Helen Hrdy promoted to CCO; Jason Hahn (CRO), Christophe Louvion (CPTO), Andy Monnich (CCDO) appointed.","Hrdy base salary raised to $400k; receives option for 100k shares vesting on $170M TRCV by Dec 2026.","Long-term cash bonus for Hrdy: zero below $170M TRCV, up to ~$8.6M at $233M TRCV (Dec 2026).","Hays receives option equal to ($63,700 × 3) / Jan 18 close price, same TRCV vesting condition.","Press release notes recent multi-million-dollar contract win with Advocate Health system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252694,"accession_number":"0001437749-24-000174","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"COO Jona S. Raasch to depart role effective Dec 31, 2023; remains with company","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On Dec 28, 2023, Jona S. Raasch notified company she would step down as COO.","Departure effective Dec 31, 2023; she will continue as an employee in other roles.","Raasch had over 30 years of service; company expressed gratitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270175,"accession_number":"0001437749-23-030911","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Q3 EPS $0.32 vs $0.33 YoY; HUP adopted by 91 orgs","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Diluted EPS $0.32 for Q3 2023, down from $0.33 in Q3 2022.","New sales grew YoY; Human Understanding Program adopted by 91 healthcare organizations.","Sequential quarterly operating margin improvement in last two quarters; focus on returning to historical margins.","Net debt ~$20M; $25M revolver available; paid $27.5M dividends, $310K buybacks in Q3.","Spent $3.7M on innovation and growth investments during quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":110579000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287153,"accession_number":"0001437749-23-021779","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research reports Q2 2023 diluted EPS $0.29, down from $0.33 YoY; new sales up 53%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Diluted EPS $0.29 for Q2 2023 vs $0.33 for Q2 2022, a 12% decrease.","New sales increased 53% compared to Q2 2022.","Human Understanding Program adopted by 39 healthcare organizations through June 30.","Capital allocation: $4.2M innovation/growth, $3.0M dividends, $1.8M share repurchases in Q2.","Operating margins improved in Q2 2023 compared to Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":72634000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307252,"accession_number":"0001437749-23-018045","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NRC amends credit agreement to exclude HQ renovation capex from covenant, cap $25M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment to Credit Agreement with First National Bank of Omaha dated June 16, 2023.","Revises Consolidated Fixed Charge Coverage Ratio to exclude unfinanced capex for HQ renovation.","Limits total HQ renovation capital expenditures to $25M from January 1, 2023, onward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307251,"accession_number":"0001437749-23-014369","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NRC annual meeting: all proposals pass with >96% support; directors elected for 3-year terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Parul Bhandari (98.15% for) and Penny A. Wheeler (96.55% for) as directors for three-year terms expiring 2026.","Ratified KPMG LLP as auditor for 2023 with 98.93% approval.","Approved on advisory basis executive compensation (98.81% for).","Advisory vote on frequency of say-on-pay: 97.24% chose one year; board to consider."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307250,"accession_number":"0001437749-23-012493","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Q1 EPS falls to $0.28 from $0.34; capital allocation unchanged","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Diluted EPS $0.28 for Q1 2023, down from $0.34 in Q1 2022.","Company funded $2.9M for innovation and growth, $3.0M for dividends, $2.0M for share repurchases.","Board maintains capital allocation priorities: innovation, M&A, dividends, buybacks.","Announced MyView to integrate patient insights into EHR to support personalized care.","Expanding sales and marketing resources for Human Understanding Program."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":36473000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326286,"accession_number":"0001437749-23-003575","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health reports Q4 EPS $0.27, down from $0.38; FY revenue +7% but EPS $1.27 vs $1.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 diluted EPS $0.27 (vs $0.38 in Q4 2021); full-year 2022 diluted EPS $1.27 (vs $1.46).","FY 2022 revenue grew 7% year-over-year driven by core Human Understanding Program; Canadian ops phase-out partially offset.","$2.6M reclassification from substantial liquidation of Canadian subsidiary impacted other expense.","Capital allocation: $21.0M dividends, $27.6M share repurchases, $12.2M innovation/growth in 2022.","New client wins including St. Bernards Healthcare; received Best in KLAS 2023 Award for Patient Experience Improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":151568000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344002,"accession_number":"0001437749-22-025653","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Corp Q3 revenue flat at $37.7M; EPS down to $0.33 from $0.38","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.7M vs $37.8M prior year; net income $8.3M vs $9.7M; diluted EPS $0.33 vs $0.38.","CFO cited investments in innovation, marketing, and associate retention as margin headwinds.","Canadian operations phase-out and non-core decline offset core growth.","Paid $5.9M in dividends and $3.6M for share repurchases in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":113424000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344001,"accession_number":"0001437749-22-023445","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"National Research increases delayed draw term loan commitment to $75M, extends maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Delayed draw-down term loan commitment raised from $15M to $75M.","Maturity of delayed draw-down and repurchase term loans extended to May 28, 2027; revolving loan to May 28, 2025.","LIBOR replaced with SOFR plus 2.35% as reference rate for interest.","Amendment with First National Bank of Omaha dated September 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":360501,"accession_number":"0001437749-22-018808","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRC Health Q2 revenue up 2% to $37.3M; diluted EPS falls to $0.33 from $0.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.3M (+2% YoY); net income $8.3M vs $8.9M; diluted EPS $0.33 vs $0.35.","Operating income decreased 6% to $11.5M; higher spending on innovation, marketing, retention.","Signed first Human Understanding Program contract with Novant Health (15 medical centers, 600 clinics).","Continued capital allocation: quarterly dividend and share repurchases in Q2.","CEO highlights organic growth focus and new Program adoption as key drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":75734000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379563,"accession_number":"0001437749-22-013292","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"NRC Health declares $0.24 quarterly dividend and authorizes up to 2.5M share repurchase","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Quarterly dividend of $0.24 per share payable July 15, 2022; record date June 30, 2022.","Board authorized repurchase of up to 2.5 million shares; no expiration date.","New buyback authorization follows completion of prior share repurchase program.","Shareholder meeting results: directors elected with >97% approval; KPMG ratified; say-on-pay approved ~98%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379562,"accession_number":"0001437749-22-013164","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"NRC Health appoints Microsoft executive Parul Bhandari to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Parul Bhandari appointed as Class II director effective May 18, 2022, term through 2023 annual meeting.","Bhandari is Microsoft's Director, Partner Strategy, Worldwide Media and Communications, with 20+ years in tech and AI.","She joins the Strategy, Nominating, and Compensation and Talent Committees.","Compensation follows standard NRC non-employee director policies as described in 2022 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":379561,"accession_number":"0001437749-22-011015","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Corp Q1 revenue up 8% to $38.4M, EPS down to $0.34","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.4M (+8% YoY), net income $8.5M vs $9.2M, diluted EPS $0.34 vs $0.36.","Operating income decreased 3% to $11.7M; expenses rose on innovation and employee benefits.","Cash from operations $8.3M, down from $14.4M; net cash position $21.8M, up from $13.8M.","CEO highlights new Human Understanding Program launch; strong client interest but gradual adoption expected."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":38441000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":397759,"accession_number":"0001437749-22-002954","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Q4 revenue +10% to $38.3M, EPS $0.38; FY revenue +11% to $148.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $38.3M (+10% YoY); operating income $12.9M (+26%); diluted EPS $0.38 vs $0.32.","Full-year 2021 revenue $148.0M (+11%); operating income $50.3M (+18%); diluted EPS $1.46 vs $1.45.","Cash flow from operations $46.3M (up 14%); net cash position $27.8M, up from $4.1M at year-end 2020.","Launched Health's Human Understanding Program to personalize patient care at scale.","Continued quarterly dividend and share repurchases funded by strong cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":147954000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":416747,"accession_number":"0001437749-21-025200","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Q3 revenue up 13% to $37.8M; EPS $0.38 vs $0.37","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.8M (+13% YoY); operating income $13.1M (+9%).","Recurring Contract Value $151.5M; Voice of Customer revenue up 20%.","Net income $9.7M vs $9.6M; diluted EPS $0.38 vs $0.37.","Cash balance $52.5M; new clients Sharp Healthcare and UConn Health."],"consensus_eps_estimate":null,"consensus_eps_actual":1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":109656000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434316,"accession_number":"0001437749-21-018648","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"National Research Q2 revenue up 17% to $36.4M; EPS rises to $0.35 from $0.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Recurring Contract Value grew 5% YoY to $149.8M.","Operating income increased 32% to $12.2M; net income $8.9M vs $7.7M.","Voice of the Customer revenue up 29% YoY; new clients include The Oregon Clinic and Foundation Health Partners.","Cash balance $48.9M; management plans to use liquidity for M&A and dividends.","Diluted EPS $0.35 for Q2 2021, up from $0.30 in Q2 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":71889000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434315,"accession_number":"0001437749-21-016301","cik":70487,"company_name":"NRC HEALTH","ticker":"NRC","form_type":"8-K","filed_at":"2021-07-02T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"National Research reincorporates to Delaware; adopts majority voting, proxy access; authorized shares raised to 110M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reincorporation from Wisconsin to Delaware, effective June 30, 2021, with 93.68% of votes for.","Uncontested director elections changed to majority vote standard; failing directors must tender resignation to board.","Proxy access permits stockholders owning 3% for ≥3 years to nominate up to 2 or 20% of board candidates.","Authorized common shares increased from 60M to 110M; all seven meeting proposals passed with strong support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":431127005.69275206,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}